322 related articles for article (PubMed ID: 22337333)
21. Reproductive and metabolic phenotype of a mouse model of PCOS.
van Houten EL; Kramer P; McLuskey A; Karels B; Themmen AP; Visser JA
Endocrinology; 2012 Jun; 153(6):2861-9. PubMed ID: 22334715
[TBL] [Abstract][Full Text] [Related]
22. Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age.
Maliqueo M; Sun M; Johansson J; Benrick A; Labrie F; Svensson H; Lönn M; Duleba AJ; Stener-Victorin E
Endocrinology; 2013 Jan; 154(1):434-45. PubMed ID: 23183180
[TBL] [Abstract][Full Text] [Related]
23. Androgens and polycystic ovary syndrome.
Nisenblat V; Norman RJ
Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):224-31. PubMed ID: 19390322
[TBL] [Abstract][Full Text] [Related]
24. A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice.
Kauffman AS; Thackray VG; Ryan GE; Tolson KP; Glidewell-Kenney CA; Semaan SJ; Poling MC; Iwata N; Breen KM; Duleba AJ; Stener-Victorin E; Shimasaki S; Webster NJ; Mellon PL
Biol Reprod; 2015 Sep; 93(3):69. PubMed ID: 26203175
[TBL] [Abstract][Full Text] [Related]
25. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys.
Abbott DH; Tarantal AF; Dumesic DA
Am J Primatol; 2009 Sep; 71(9):776-84. PubMed ID: 19367587
[TBL] [Abstract][Full Text] [Related]
26. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome.
Arroyo P; Ho BS; Sau L; Kelley ST; Thackray VG
PLoS One; 2019; 14(9):e0223274. PubMed ID: 31568518
[TBL] [Abstract][Full Text] [Related]
27. Obesity and the polycystic ovary syndrome.
Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
[TBL] [Abstract][Full Text] [Related]
28. Hypothalamic kiss1 mRNA and kisspeptin immunoreactivity are reduced in a rat model of polycystic ovary syndrome (PCOS).
Brown RE; Wilkinson DA; Imran SA; Caraty A; Wilkinson M
Brain Res; 2012 Jul; 1467():1-9. PubMed ID: 22668987
[TBL] [Abstract][Full Text] [Related]
29. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
Abbott DH; Barnett DK; Bruns CM; Dumesic DA
Hum Reprod Update; 2005; 11(4):357-74. PubMed ID: 15941725
[TBL] [Abstract][Full Text] [Related]
30. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications.
Diamanti-Kandarakis E
Expert Rev Mol Med; 2008 Jan; 10():e3. PubMed ID: 18230193
[TBL] [Abstract][Full Text] [Related]
31. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
Otto-Buczkowska E; Jarosz-Chobot P; Deja G
Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
[TBL] [Abstract][Full Text] [Related]
32. Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome.
Schuring AN; Schulte N; Sonntag B; Kiesel L
Gynakol Geburtshilfliche Rundsch; 2008; 48(1):9-15. PubMed ID: 18209494
[TBL] [Abstract][Full Text] [Related]
33. Exposure to a Healthy Gut Microbiome Protects Against Reproductive and Metabolic Dysregulation in a PCOS Mouse Model.
Torres PJ; Ho BS; Arroyo P; Sau L; Chen A; Kelley ST; Thackray VG
Endocrinology; 2019 May; 160(5):1193-1204. PubMed ID: 30924862
[TBL] [Abstract][Full Text] [Related]
34. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
[TBL] [Abstract][Full Text] [Related]
35. Interrelationship between excessive levels of circulating androgens in blood and ovulatory failure.
Parker CR; Mahesh VB
J Reprod Med; 1976 Aug; 17(2):75-90. PubMed ID: 134158
[TBL] [Abstract][Full Text] [Related]
36. Polycystic ovarian disease: animal models.
Mahajan DK
Endocrinol Metab Clin North Am; 1988 Dec; 17(4):705-32. PubMed ID: 2973982
[TBL] [Abstract][Full Text] [Related]
37. Endometrial abnormality in women with polycystic ovary syndrome.
Shang K; Jia X; Qiao J; Kang J; Guan Y
Reprod Sci; 2012 Jul; 19(7):674-83. PubMed ID: 22534323
[TBL] [Abstract][Full Text] [Related]
38. Polycystic ovary syndrome and type 2 diabetes mellitus.
De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
[TBL] [Abstract][Full Text] [Related]
39. The impact of obesity on reproduction in women with polycystic ovary syndrome.
Pasquali R; Gambineri A; Pagotto U
BJOG; 2006 Oct; 113(10):1148-59. PubMed ID: 16827825
[TBL] [Abstract][Full Text] [Related]
40. Parametrial adipose tissue and metabolic dysfunctions induced by fructose-rich diet in normal and neonatal-androgenized adult female rats.
Alzamendi A; Castrogiovanni D; Ortega HH; Gaillard RC; Giovambattista A; Spinedi E
Obesity (Silver Spring); 2010 Mar; 18(3):441-8. PubMed ID: 19696763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
